Arthritis Foundation Patient Insights. Understanding, Serving and Helping Millions of People With Arthritis

Similar documents
Introduction. Arthritis Foundation Arthritis Advocacy Toolkit

ABOUT LUNG CANCER ALLIANCE

Arthritis. Canada s most common chronic health condition. About the Arthritis Society

HEALTH ADVOCACY: THE KEY TO OUR FUTURE

Arthritis Foundation

VOLUME 2, 2018 Advocacy: The Critical First Step Lupus Insight Prize Patient Involvement Lupus News Corner ADVOCACY Lupus Awareness Month

An Active Inclusive Capital. A Strategic Plan of Action for Disability in London

2018 Upcoming Activities & Accomplishments. Approved language: how we talk about our initiatives

Bringing Together Clinical, Economic and Patient Reported Outcomes Data Future Of Real World Evidence. March IIeX Health, Philadelphia, PA

C-Change Making the Business Case Questions & Answers

The Dental Therapist Project: Expanding Care to Every Community

Engaging Patients in Research to Increase Efficiency and Generate Real-World Data

Carers Australia Strategic Plan

SUPPORT FEDERAL FUNDING FOR PARKINSON S DISEASE RESEARCH AND DRUG DEVELOPMENT

STRATEGIC PLAN

Agenda 2030: One Nation Labour s Plan for science Response from Alzheimer s Research UK

Impacting Policy, Changing Lives: How to Effectively Engage Consumers in Advocacy

Criminal Justice in Arizona

Championing patients every step of the way

Patient and Public Involvement, Engagement and Participation Strategy NIHR Newcastle Clinical Research Facility

CONSTITUENT VOICE FISCAL YEAR 2016 RESULTS REPORT

Claire Severgnini Chief executive - National Osteoporosis Society

2018 AFP INTERNATIONAL COMMITTEE DESCRIPTIONS

Help prevent the misuse, abuse and diversion of ADHD prescription stimulants among college students. August 5, 2015

ADVOCATING FOR PATIENTS WITH DIABETES

PARTNERS FOR A HUNGER-FREE OREGON STRATEGIC PLAN Learn. Connect. Advocate. Partners for a Hunger-Free Oregon. Ending hunger before it begins.

Strategic Direction. At The Kids Cancer Project our vision is to find a cure for kids cancer

Coalition for Suicide Prevention in Clackamas County Launch Meeting. Tuesday October 16, :30 pm to 6:30 pm Oregon City Library

Homelessness is a complex issue but it is not an unsolvable problem. It can be ended and philanthropy has a vital role to play.

Strategic Plan Executive Summary Society for Research on Nicotine and Tobacco

THE CARDIFF COMMITMENT TO YOUTH ENGAGEMENT AND PROGRESSION: REPORT OF DIRECTOR OF EDUCATION & LIFELONG LEARNING

Carla Knapp, National Director Native Services

February 13, The Honorable Fred Upton 2183 Rayburn House Office Building Washington, DC Dear Chairman Upton:

Insights from the Kaiser Permanente database

Strategic Plan

September 2017 A LOOK AT PARP INHIBITORS FOR OVARIAN CANCER. Drugs Under Review. ICER Evidence Ratings. Other Benefits. Value-Based Price Benchmarks

0 to 60. HIV/AIDS Advocacy in North Carolina. Patrick M. Lee, Project Director Piedmont HIV Health Care Consortium North Carolina AIDS Action Network

A LOOK AT ABUSE-DETERRENT OPIOIDS

Leading for Impact. $8.5 million through 215 grants. $4.5 million highlights:

Guide to Understanding and Managing Arthritis

Arthritis Foundation Ambassador Program August Recess Guide 2017

California HIV/AIDS Research Program

Testimony of Mr. David Guth, CEO, Centerstone America. Combating the Opioid Crisis:

CONGRESSIONAL CHECK UP

Statement by Dr Marcos Espinal at the ECOSOC High-Level Segment, 6 July Madam President, Esteemed Delegates, Ladies and Gentlemen.

Module 6: Substance Use

Welcome to Dr. Judy Salerno! Komen Research Highlights Shared with Affiliate Community. Table of Contents:

SECTION 3: WHAT DOES DIABETES UK DO?

One in every five adults and 300,000 children

Strategic Plan

Join Today -- Be a part of something BIG that will make a difference for Oroville!

One in every five adults and 300,000 children

2017 Campaign Presentation Guide

Patients Driving Progress

U.S. Fund for UNICEF Campus Initiative LEADERSHIP TRANSITION HANDBOOK

Comprehensive Cancer Control Technical Assistance Training and Communication Plan. PI: Mandi Pratt-Chapman, MA. Cooperative Agreement #1U38DP

For Tardive Dyskinesia

2017 ALZHEIMER'S DISEASE FACTS AND FIGURES

Edith T. Moricz COVER PAGE. MBA Founder & CEO of BeyondSuccessOnline.com

WomenHeart Science & Leadership Symposium at Mayo Clinic

Adding Tomorrows. Corporate Engagement with the. KENNEDY, age 8

MEMBERSHIP REPORT A MESSAGE FROM THE EXECUTIVE DIRECTOR MEMBERSHIP

universities fighting world hunger getting started on your campus

Illinois Diabetes Action Plan: What s In It for You?

What is Relationship Coaching? Dos and Don tsof Relationship Coaching RCI Continuing Education presentation

Shaping our future. Our strategy for

2018 Candidate Guide. Leading in the fight to end Alzheimer's

Testimony of Robert Egge, Vice President of Public Policy Alzheimer s Association. December 8, 2010

OUR MISSION: SUPPORT, EDUCATION AND RESEARCH

We re for all women. No exclusions, no judgement.

Implementing and Sustaining Chronic Disease Self-Management Education Programs

PARTNERING WITH HEARTKIDS

The Kirwan Institute is entering its second decade of working to create a just and inclusive

MOVEMBER FUNDED MEN S HEALTH INFORMATION RESOURCES EVALUATION BRIEF. 1 P age

Wrap up of 2015 Idaho Legislative Session

21 st Century Cures Initiative

Fast-Forwarding a Cure for Melanoma

I. CHESTER COUNTY COMMUNITY FOUNDATION GRANT PROPOSAL SUMMARY SHEET Date September 20, 2018

Dr. Gigi Osler Inaugural address Dr. Gigi Osler President Canadian Medical Association Winnipeg, Man. August 22, 2018 Check against delivery

The Essential Role of the Healthcare Consumer

49, ,280,198 3,740 SERVING THE PUBLIC AS RESEARCHER AND WATCHDOG GIVING BACK THROUGH SCHOLARSHIP PROGRAMS MOVING THE PUBLIC 60,400

Public Health Federal Funding Request to Address the Opioid Epidemic

CPRIT Overview. Cancer Centers Administrators Forum April 4, 2016

Chief Development Officer National Brain Tumor Society

VISION MISSION GOALS TO BE CONNECTED IN SERVICE TO PROVIDE ENOUGH FOOD FOR ALL TO LEVERAGE FOOD AS A COMMUNITY CATALYST

Painfully frustrating

August Monthly Call Agenda. Attendees: Teerith, Shahil, Steve, Carol, Emily, Abha, Jan, Marisa, Nancy, Dottie, and Melissa

What needs to happen in England

Shaping our future: a call to action to tackle the diabetes epidemic and reduce its economic impact

RESEARCH EDUCATION COMMUNITY STRATEGIC PLAN

Looking to the Future in HIV Prevention:

The HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA)

Engaging with FDA: A Guide for Foundation Funders of Research. FasterCures Webinar Series presents. April 18, 2012

SparkPoint Contra Costa: Deeper Dive into Advocacy

OPIOID WORKGROUP LEADERSHIP TEAM

Raises national profile Legislative advocacy with allied organiations Restored rights to students with drug convictions Enacted the Second Chance Act

LPI : Leadership Practices Inventory

Table of Contents. 2 P age. Susan G. Komen

MENTAL HEALTH AND WELLNESS OUTCOME OF THE TOWN HALL

About ACPA... Our Mission...

Transcription:

Arthritis Foundation Patient Insights Understanding, Serving and Helping Millions of People With Arthritis

In the United States, 54 ADULTS 1IN 4 have doctor-diagnosed arthritis. 2/3 are under the age of 65, including 300,000 CHILDREN. It s common among athletes and those with physicallydemanding jobs. OUR SERVICEMEN AND WOMEN ARE AT THE FOREFRONT OF THIS GROWING CRISIS. Arthritis damages vital organs and makes other conditions worse, resulting in Besides preventing people from performing everyday tasks, arthritis ARTHRITIS PREVALENCE Arthritis is preventable and treatable, not simply an 100 DOCTOR VISITS 7 HOSPITALIZATIONS every year. And it contributes to early death in combination with other diseases. keeps them from doing the things they love. It can cause depression and feelings of being left out of life. It costs the U.S. health care system $303.5 BILLION per year. Conquering arthritis is the first step in alleviating this financial burden on our health care system. unavoidable consequence of aging yet research into arthritis is chronically underfunded. By reaching and listening to millions of people with arthritis, the Arthritis Foundation is capturing what matters most to patients working together to develop resources, influence research and change systems to improve lives.

The Arthritis Foundation is the Champion of Yes. Leading the fight for the arthritis community, the Arthritis Foundation helps conquer everyday battles through life-changing information and resources, access to optimal care, advancements in science and community connections. Our goal is to chart a winning course, guiding families in developing personalized plans for living a full life and making each day another stride towards a cure. POSITIVE IMPACT We guide the arthritis community to take action through ADVOCACY AT THE STATE AND FEDERAL LEVELS surpassing 100 state legislative victories since 2014 and growing the Congressional Arthritis Caucus to 146 members in 2018. The Live Yes! Arthritis Network, created by the Arthritis Foundation, makes CONNECTIONS BOTH IN PERSON AND ONLINE to empower people to live their best life. People with arthritis find strength in each other, manage stress and take control of their health care. 23% more likely to agree that there are things a person with arthritis can do to MAKE LIFE BETTER INFORMATION & CONNECTIONS HAVE A POSITIVE IMPACT. People who engage with the Arthritis Foundation are taking more positive actions compared to those with arthritis who are not engaged. 52% SINCE 1948 $500 + more likely to SEEK TREATMENT from a doctor 47% more likely to start a WEIGHT LOSS program INVESTED IN ARTHRITIS RESEARCH. Arthritis Foundation-funded scientists were key to the discovery of biologics and other major interventions, changing the future for all forms of arthritis. 39% more likely to EAT HEALTHIER 14% more confident in their ability to PURSUE GOALS

THE ARTHRITIS FOUNDATION IS PRESENT WHERE PEOPLE NEED US 1.3 Our national footprint aligns with communities of greatest need PEOPLE engage with digital resources and local events. Arthritis Foundation Reach Map Arthritis Prevalence Map Source: CDC prevalence by county www.cdc.gov/arthritis/data_statistics/state-data-current.htm Source: Affinity Database, November 2018 Alaska Alaska Hawaii Hawaii Puerto Rico Guam Since the 1940s, the number of Americans with arthritis has risen significantly. 1948 1958 1968 1978 1988 1998 2008 54 7.5 11 16 31 37 43 46 22 PEOPLE per year seek information on arthritis.org

TOP 6 AREAS THAT MATTER MOST TO PATIENTS The Arthritis Foundation conducts over 50 surveys per year (generating between 500 3,000 responses per survey) to ensure our research and resources remain relevant to patient needs. 1 PHYSICAL PAIN IS A BIG DEAL 50% reported that PAIN IMPACTS THEM AT LEAST 10 DAYS PER MONTH* 32% reported that PAIN IMPACTS THEM AT LEAST 20 DAYS PER MONTH* 2 3 NUTRITION MATTERS 84% believe a HEALTHY DIET IS IMPORTANT FOR MANAGING ARTHRITIS* ARTHRITIS PAIN IS MORE THAN JUST PHYSICAL 48% FEEL DOWN, DEPRESSED OR HOPELESS* 57% FEEL LITTLE INTEREST OR PLEASURE IN DOING THINGS* 70% of juvenile arthritis parents FEEL NOBODY UNDERSTANDS HOW ARTHRITIS AFFECTS THEIR CHILD* 4 MEDICAL OUTCOMES 6 ARE IMPORTANT* Top 5 outcomes of interest to patients: 1. Reduce pain 2. Increase overall health 3. Slow disease progression 4. Do more of what I want to do 5. Prevent joint damage 5 DAILY LIVING CAN BE DIFFICULT* What people find difficult Get in and out of a vehicle: 68% Pick something up off floor: 54% Climb in and out of bed: 47% Dress oneself: 42% What makes products hard to use: Difficult to use with my hands: 68% Difficult to open containers: 66% Difficult to lift: 63% Too heavy to use/push: 61% ACCESS IS KEY* Top 6 insurance issues/challenges: 1. Prior authorization 2. High deductibles 3. High coinsurance for medications 4. High premiums 5. Changes to drug formulary 6. Step therapy (fail first) Top 6 reasons why patients have difficulty taking their medications: 1. Side effects/how the meds make them feel 2. Cost 3. Problems with pharmacy or mail order delivery 4. Unexpected prescription charge 5. Difficulty with self-injection 6. Limited or no access to doctor or health care professionals *Based on Arthritis Foundation original research, backed by Nielsen/Harris Poll, patients have shared what matters most to them.

Network PROMISE The Live Yes! Arthritis Network, created by the Arthritis Foundation, makes connections both in person and online to empower people to live their best life. People with arthritis find strength in each other, manage stress and take control of their health care. Network AGENDA The Arthritis Foundation s Live Yes! Arthritis Network is transforming how people with arthritis live life with less pain and are more active in their care. Network IMPACT The Arthritis Foundation s Live Yes! Network impacts 3 key areas of Patient-Reported Outcomes (PROs). People with arthritis will experience: Improved Physical Health Participants will function better and be able to carry out more daily activities with less pain interference. Improved Emotional & Social Health Participants will better manage stress and depression to improve their enjoyment of life. They will connect with others who share their same journey to boost a sense of belonging. Better Experience of Care Participants will gain tools to proactively take control of their care by better communication with their health care team. PERSONAL APPROACH Patient-Reported Outcomes The Live Yes! Arthritis Network provides real-time Patient Reported Outcomes that will shape the future of arthritis care and treatment. These PROs serve three distinct needs: 1. Allow patients to better understand and track their health over time. 2. Enable the Arthritis Foundation to tailor programming to specific market needs based on participants aggregate data. 3. Help researchers understand patient health trends leading to more effective treatments. LIVE YES! INSIGHTS In 2018, the Arthritis Foundation launched an initial set of Patient-Reported Outcome Measures comprised of established, research-backed measures. RESULTS WERE POWERFUL. The survey measured three primary domains: Physical Health In addition to getting a national/average baseline of results across these domains, the Foundation was able to look at results market by market. Based on findings, local markets will be able to offer targeted programming to move the needle in their area. Some key findings include: Emotional Health TOP 4 ABOVE THE NATIONAL AVERAGE IN OUR PRIMARY DOMAINS Physical Health Massachusetts Pittsburgh Colorado DC Metro Emotional Health DC Metro Greater Chicago Pittsburgh Colorado Experience of Care Alabama & Mississippi Northern New England Los Angeles Kansas Experience of Care Within 2 weeks, 5,040 PEOPLE PARTICIPATED IN THE SURVEY. DISEASE TYPES Osteoarthritis 30% Rheumatoid Arthritis 22% Fibromyalgia 9% Osteoporosis 7% Psoriatic Arthritis 4% Sjogren s Syndrome 4% Ankylosing Spondylitis 3% Juvenile Arthritis persistent to adulthood 2% Gout 2% Lupus 2% Unknown 2% Other 13% AGE 75+ 13% 65-74 29% 55-64 28% 45-54 16% 35-44 7% 34 or younger 7%

TAKING PATIENT-REPORTED OUTCOMES TO THE NEXT LEVEL The Arthritis Foundation is not only leveraging patient insights, stories and selfreported outcomes to influence internal strategies, but to influence external stakeholders and systems as well. A few highlights: OA Patient-Focused Drug (PFDD) Meeting The Arthritis Foundation hosted an OA Patient-Focused Drug Development (PFDD) meeting in the Washington, D.C., area on March 8, 2017. This meeting provided the U.S. Food and Drug Administration (FDA), drug developers, health care providers, academic researchers and other stakeholders an opportunity to hear directly from patients, patient advocates and caretakers about the signs and symptoms that matter most to them. OA patients shared just how much this disease impacts their lives, as well as the gaps in treatment and what they are looking for in ideal, new treatment options. Results: FDA released new OA guidance for industry citing the shortcomings of current study endpoints to address how patients function and feel. JIA Patient-Focused Drug (PFDD) Meeting Hundreds of patients and their families, FDA staff, industry leaders and researchers convened in Washington, D.C., to participate in the externally-led JIA Patient-Focused Drug Development (PFDD) meeting on August 2, 2018. This meeting provided an opportunity for patients, patient advocates and caretakers to talk about the symptoms and issues that matter most to them. JIA parents and their families shared information about the impact of JIA on daily life, the symptoms that are most challenging, experiences with currently available treatments and the need for new and different treatments. Influencing the Institute for Clinical and Economic Review (ICER) On March 24, 2017, after many months of review, the Institute for Clinical and Economic Review (ICER) held a public meeting in Boston, MA, to discuss evidence findings on treatments for rheumatoid arthritis (RA). ICER is a nonprofit organization that reviews the effectiveness of medications and their costs. During the meeting, the Foundation played a vital role, presenting patient-centered research, asserting the patient voice and displaying strong leadership on behalf of the arthritis community. We presented data from our two patient surveys conducted over the previous months (3,745 respondents total), helping the panel better understand innovative biologic therapies, patient treatment perspectives and utilization management statistics. Panelists were shocked to learn that almost half of the surveys respondents had to go through step therapy and, of those, 22 percent had to repeat the steps when their insurance changed, even if they were stable on their drug. Members of our advocacy program Anna Legassie, Renay Houlem and Jen Melanson also played a critical role at the ICER meeting, powerfully representing the patient perspective. Every voting member of the ICER panel noted that our Advocates testimony significantly impacted their knowledge and understanding of the issues. Results: ICER deemed it did not have enough evidence to determine that a given biologic was more cost-effective than another. Results: A written report will be published in early 2019, setting the stage for deeper community engagement between regulators, patients, researchers and the Arthritis Foundation.

References 1. Arthritis Foundation Consumer Needs Study, conducted by Nielsen/Harris, July 2016 (AF members n=722 & Non-AF members n=615) 2. Arthritis Foundation Consumer Usage Study, conducted by Nielsen/Harris, March 2016 (Diagnosed with Arthritis: n=706; General Public: n=714) 3. Arthritis Foundation Advocacy Priorities Report, September 2018 (n= 1,744) 4. Arthritis Foundation Nutrition Survey, May 2018 (n= 855) 5. Arthritis Foundation OA Patient-Focused Drug Development Survey & Focus Group Report, March 2017 (n=345) 6. Arthritis Foundation Patient Reported Outcome Survey, October 2018 (n= 5,040) 7. Arthritis Foundation survey of rheumatoid arthritis patient treatment experiences, for Discussion with ICER, November 2016 (n= 3,186) 8. Arthritis Foundation survey to determine impact of innovative therapies on rheumatoid arthritis patients, for Discussion with ICER, December 2016 (Biologic naïve for 5 years or more n=222 & Biologic experienced within 5 years n=337) 9. Center for Disease Control (CDC): https://www.cdc.gov/arthritis/data_statistics/arthritis-related-stats.htm To learn more about the Live Yes! Arthritis Network, go to: arthritis.org/liveyes